Synpromics is now integrated as part of a greater gene therapy platform as part of the AskBio family of companies, operating as a wholly owned subsidiary
Prior to its acquisition by AskBio, Synpromics raised total funds of £7.4M from Friends & Family, Scottish Investment Bank, and Calculus Capital.
In addition, the company has been supported by numerous grant awards from Scottish Enterprise, InnovateUK and IBioIC, to the value of a further £3.5M of non-dilutive funding.
Founded in 2001, Asklepios BioPharmaceutical, Inc.(AskBio) is a privately held, clinical-stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10TM and an extensive AAV capsid library.
Based in Research Triangle Park, N.C., the company has generated hundreds of proprietary third-generation gene vectors, several of which have entered clinical testing. An early innovator in the space, the company holds more than 500 patents in areas such as AAV production, chimeric vectors, and self-complementary DNA.
AskBio maintains a portfolio of clinical programs across a range of indications including Pompe, Limb Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy, Hemophilia (Chatham Therapeutic/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer).